🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. erlotinib [Tarceva]

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  2. evorpacept

    ALX ONCOLOGY HOLDINGS INC

    Head and Neck Cancer

    phase 2 small molecule active

    2 trials

  3. experimental group x-MAP

    The First People's Hospital of Lianyungang

    Metastatic Colorectal Cancer (mCRC)

    phase 2 other active

    1 trial

  4. farletuzumab ecteribulin

    Bristol-Myers Squibb Australia Pty Ltd

    Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  5. farletuzumab ecteribulin, LENVIMA 4 mg hard capsules, LENVIMA 10 mg hard capsules

    Eisai Co.,

    Solid tumors in 4 tumor types: platinum resistant ovarian cancer, triple-negative breast cancer (TNBC), endometrial cancer (EC), and non-small cell lung cancer adenocarcinoma; NSCLC).

    phase 2 small molecule active

    1 trial

  6. favezelimab, quavonlimab, Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Lenvatinib

    Merck Sharp and Dohme

    Stage IV non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  7. fruquintinib

    Takeda

    Colon Cancer

    phase 2 small molecule active

    1 trial

  8. furmonertinib

    Sun Yat-sen University

    Non-small Cell Lung Cancer Metastatic

    phase 2 small molecule completed

    1 trial

  9. hyperbaric oxygen

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 small molecule active

    1 trial

  10. inhaled delta-8-THC 300mcg or 600mcg per dose

    Teva Pharma GmbH

    Cancer

    phase 2 small molecule terminated

    1 trial

  11. ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab

    Second Affiliated Hospital of Soochow University

    Liver Cancer

    phase 2 small molecule active

    1 trial

  12. leucovorin, oxaliplatin, docetaxel, S-1

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  13. lurbinectedin, JEMPERLI 500 mg concentrate for solution for infusion

    The George Institute

    Advanced/Recurrent Endometrial Cancer Patients with Disease Progression after Prior Therapy with Platinum-based Chemotherapy

    phase 2 small molecule active

    1 trial

  14. mFOLFOX6 + BIBF 1120

    Galmed Pharmaceuticals

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  15. mFOLFOXIRI

    The First People's Hospital of Lianyungang

    Locally Advanced Rectal Cancer

    phase 2 small molecule active

    1 trial

  16. mRNA-4157, BCG VACCINE

    Merck Sharp and Dohme

    Bladder cancer

    phase 2 small molecule active

    1 trial

  17. megestrol acetate oral suspension + serplulimab + SOX

    The First People's Hospital of Lianyungang

    Stage III Gastric Cancer

    phase 2 small molecule active

    1 trial

  18. nab-paclitaxel

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer

    phase 2 small molecule active

    1 trial

  19. nanoliposomal irinotecan

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head & Neck Cancer

    phase 2 small molecule completed

    1 trial

  20. nanoparticle albumin-bound paclitaxel/carboplatin

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  21. neoadjuvant anti-PD-1

    Shanghai Chest Hospital

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

  22. neratinib

    PUMA BIOTECHNOLOGY, INC.

    HER2-mutant Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  23. oncolytic adenovirus expressing GMCSF

    CG Oncology

    Bladder Cancer

    phase 2 mab terminated

    1 trial

  24. online adaptive radiotherapy

    The First People's Hospital of Lianyungang

    Cervical Cancer

    phase 2 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources